Recent advances in adjuvant therapy for breast cancer

Seminars in Oncology Nursing

Volumn 19, Issue SUPPL. 2, 2003, Pages 10-16

  Palmieri, Frances M ^a   Perez, Edith A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHYLTESTOSTERONE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TAXANE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ENZYME INHIBITOR;

ADJUVANT CHEMOTHERAPY; ANEMIA; ASTHENIA; BLOOD TRANSFUSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CANCER; HEALTH CARE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL RESEARCH; NEUTROPENIA; NURSING; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; BREAST TUMOR; FEMALE; ONCOLOGY NURSING; STANDARD; SURVIVAL; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; ONCOLOGIC NURSING; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 1342288106     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2003.09.004     Document Type: Article

References (29)

1. Mincey BA, Palmieri FM, Perez EA: Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist 7:246-250, 2002
2. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
3. Tan AR, Swain SM: Adjuvant chemotherapy for breast cancer: An update. Semin Oncol 28:359-376, 2001
4. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
5. Buzdar AU, on behalf of the ATAC Trialists' Group: The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-Updated efficacy results based on a median follow-up of 47 months. Available at: http://www.abstracts-on-line.com/abstracts/BCS/search/result-s. asp? Num=0%2E8885615 (abstr 13) (accessed March 2003) Poster presented at the 25th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 11-14, 2002
6. Piccart MJ, Lohrisch C, Duchateau L, Buyse M: Taxanes in the adjuvant treatment of breast cancer: Why not yet? J Natl Cancer Inst Monogr 30:88-85, 2000
7. Aapro MS: Adjuvant therapy of primary breast cancer: A review of key findings from the 7th International Conference, St Gallen, February 2001. Oncologist 6:376-385, 2001
8. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
9. Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
10. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
11. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5:353-360, 2000
12. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999
13. Demetri GD, Gabrilove JL, Blasi MV, et al: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 3:45-51, 2002
14. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003
15. Tchen N, Juffs H, Yi Q-L, et al: Fatigue, menopausal symptoms and their interaction in 100 women receiving adjuvant chemotherapy for breast cancer and 100 age-matched controls: Results of a prospective cohort study. Proc Am Soc Clin Oncol 21:388a, 2002 (abstr 1548)
16. Lawless GD, Ford JM: Cumulative prevalence of anemia in early-stage breast cancer (ESBC) patients. Blood 96:390b, 2000 (abstr 5447)
17. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin alfa in patient with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
18. Hudis C, Williams D, Gralow JR, and the PROCRIT Study Group: Epoetin alfa maintains hemoglobin and quality of life in breast cancer patients receiving conventional adjuvant chemotherapy: Final report. Proc Am Soc Clin Oncol 22:767, 2003 (abstr 3084)
19. O'Shaughnessy J, Vukelja S, Savin M, et al: Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: Analysis of 6-month follow-up data. Breast Cancer Res Treat 76:8138, 2002 (suppl 1) (abstr 550)
20. de Jong N, Courtens AM, Abu-Saad HH, et al: Fatigue in patients with breast cancer receiving adjuvant chemotherapy: A review of the literature. Cancer Nurs 25:283-297, 2002
21. Berger AM, Walker SN: An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy. Nurs Res 50:42-52, 2001
22. Berger AM, Higginbotham P: Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncol Nurs Forum 27:1443-1448, 2000
23. Mock V, Burke MB, Sheehan P, et al: A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 21:899-907, 1994
24. Mock V, Dow KH, Meares CJ, et al: Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24:991-1000, 1997
25. Mooney KH, Ferrell BR, Nail LM, et al: 1991 Oncology Nursing Society Research Priorities Survey. Oncol Nurs Forum 18:1381-1388, 1991
26. Robinson KD, Posner JD: Patterns of self-care needs and interventions related to biologic response modifier therapy: Fatigue as a model. Semin Oncol Nurs 8:17-22, 1992 (suppl 1)
27. Mock V, Pickett M, Ropka ME, et al: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 9:119-127, 2001
28. Denmark-Wahnefried W, Peterson BL, Winer EP, et al: Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19:2381-2389, 2001
29. Del Mastro L, Venturini M, Lionetto R, et al: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721, 1997